US Acute Myeloid Leukemia Market to 2028

Market Overview:

The US Acute Myeloid leukemia Market is expected to witness more promising growth due to advancement in treatment approaches, increases healthcare costs and expenditure, growing investments in Research and Development, and a constant growth in population. Advancement in therapeutic approaches, including targeted therapies, immunotherapies, checkpoint inhibitors, and personalized medicines, have revolutionized AML treatment, boosting patient satisfaction and reducing side effects.

Rising healthcare expenditures have expanded access to specialized diagnostics and treatments, with a surge in medical insurers facilitating affordability. Investments in R&D have resulted in innovative product launches, heightening consumer satisfaction and propelling market expansion. The surging US population has led to a higher prevalence of AML cases, intensifying demand for treatment options, diagnostic services, and supportive care. This demographic trend accelerates the urgency for accessible, advanced therapies, fostering a multifaceted demand that catalyzes market growth and stimulates further research endeavors. With a projected CAGR of 10.5% during the forecast period (2022-2028), the US AML market stands poised for robust progression, underpinned by its convergence of medical innovation, financial accessibility, and population dynamics.

The ecosystem of US Acute Myeloid Leukemia Market is characterized by dynamic interplay of pharmaceutical giants, diagnostic companies, hospitals that are providing treatment for Acute Myeloid leukemia, and health insurance providing companies that help in getting easy and affordable treatment to the diagnosed patients. The top dominant companies in the pharmaceutical sector which are driving the market growth are Pfizer Inc., Bristol Myers Squibb, Novartis, and AbbVie. The top Diagnostic companies leading the market are Abbott Laboratories and Roche Diagnostics. The leading hospital in the market providing quality treatment are MD Anderson Cancer Center and Mayo Clinic. The health insurance companies helping the diagnosed patients are United Health Group and Anthem Inc.

US Acute Myeloid Leukemia Market Analysis

• Acute Myeloid Leukemia represents 1% of all the new cancer diagnoses found in US and has a five-year survival rate of around 29%. According to the American Society of Clinical Oncology in 2021, around 20,250 people were diagnosed with Acute Myeloid Leukemia and it is estimated that there will be around 59,600 new cases and around 23,709 deaths from Leukemia of all kinds in 2023.
• New and advanced technologies are creating innovations such as targeted therapies, checkpoint inhibitors, personalized medicines, and immunotherapies, which help to enhance treatment efficiency and moreover it minimizes the side effects of treatment, leading to high patient satisfaction, survival, and remission rates.
• Increasing healthcare expenditure leading to greater access to advanced technologies, specialized treatments, and therapies. The rise in healthcare expenditure is a result of increased healthcare costs as the cost of healthcare and medical services increase at a faster rate compared to the cost of other goods and services.
• As a rescue to high healthcare services cost, heath insurance companies come to the rescue, health insurance provides diagnosed patients with affordable treatment covers and provides improved access to healthcare services without being burdened by full cost of treatments.
• Increased investments in the R&D process initiates new product launches and effective treatment approaches which drive the growth of US acute Myeloid Leukemia Market. The research industry of US accounted for 70% of US health and medical investment in 2020.

Key Trends by Market Segment:

By Treatment Type: In terms of treatment type the market is segmented into chemotherapy, targeted therapy, hormone therapy, Immunotherapy, and others. In 2022, there is a rise in the dominance of targeted therapy, as unlike traditional chemotherapy, targeted therapy focuses on specific molecule markers within cancer cells, which minimize the damage to the healthy cells. The targeted therapy offers improved results with fewer side effects.

By End-User Industry: The market is segmented by End-User industry into hospitals, homecare, specialty centers, Pharmacies, and others. Among these specialty centers were the dominant end-user industry in 2022, as they provide specialized expertise, cutting-edge treatments, and supportive care for Acute Myeloid Leukemia patients. Hospitals also play a crucial role in the initial stages but specialty centers provide focused attention and advanced therapies.

By Geography: The US Acute Myeloid Leukemia Market is Segmented into North, East, South, and West region of US. In 2022, the Northern region of US was the most dominant region in Acute Myeloid Leukemia Market.

The northern region of US is home to several renowned medical and research institutions. These institutions have strong oncology departments. They have significant investments in research and development, and driving advancements in AML treatment.

Additionally, the northern region of US has a higher population density which contributes to higher number of Acute Myeloid Leukemia cases and greater access to specialized medical services.

Competitive Landscape:

• The US Acute Myeloid Leukemia Market is characterized by intense competition and features numerous prominent participants who are involved Acute Myeloid Leukemia Market. Among the leading contenders in the US Acute Myeloid Leukemia Market are Pfizer Inc., Bristol Myers Squibb, Novartis, and AbbVie, Amgen, Janssen Pharmaceuticals, Takeda Pharmaceuticals
• The US Acute Myeloid Leukemia Market features a dynamic competitive landscape with a mix of pharmaceutical giants, biotechnology innovators, diagnostics centers, health insurance companies, and healthcare institutions.
• Intense competition in the market is driving a surge in technology adoption. Players are embracing cloud-based solutions, AI-driven analytics, and digital platforms to enhance efficiency, streamline processes, and offer personalized loan experiences, fostering a tech-driven competitive edge.
• Academic medical centers and specialized hospitals offer comprehensive patient care and innovative clinical trials. Collaborations between these entities further drive innovation, with diagnostic companies like Abbott and Roche enhancing AML detection. The landscape is propelled by advancing treatments, personalized approaches, and research breakthroughs. Ultimately, the competition centers around providing more effective, safer, and accessible treatments while responding to the evolving needs of AML patients and reshaping the trajectory of the market.

Recent Developments:

• December 2017, Pfizer announced that, the Food and Drug Administration (FDA) of US approved Bosutinib for the treatment of patients with chronic myelogenous leukemia (CML).
• In January 2020 Bristol Myers Squibb received the US FDA’S approval for Onureg for the treatment of adult patients with AML. Moreover, Novartis AG is developing a combination drug (MBG453, Venetoclax, Azacitidine) for the treatment of Acute Myeloid Leukemia, which is in phase 2 of clinical trials.
• June 2021, Bristol Myers Squibb received approval from European Commission for Onureg, a Frontline oral maintenance therapy for adult patients with acute Myeloid Leukemia who achieved their first complete remission (CR) or CR with incomplete blood count recovery following intensive induction chemotherapy.
• In December 2022, Pfizer announced its collaboration with Gero’s machine learning technology platform to discover potential therapeutic targets for fibrotic using large-scale human- based data.

Future Outlook:

• US Acute Myeloid Leukemia Market is expected to show increasing and is expected to grow at a CAGR of 10.5% from 2022 to 2028 with advancement in treatment approaches, increases healthcare costs and expenditure, growing investments in Research and Development, and a constant growth in population.
• The ongoing development of targeted therapies, immunotherapies, and personalized medicines is expected to further elevate treatment outcomes by minimizing side effects and enhancing efficacy. This precision-focused approach will likely shape the standard of care, optimizing patient experiences and survival rates.
• The expansion of telehealth and remote monitoring will improve patient access to specialized care and clinical trials. As healthcare policies evolve, equitable access to cutting-edge treatments may become more attainable.
• Patient-centric care models, alongside growing awareness and patient advocacy efforts, will influence treatment decision-making and ensure holistic support. Overall, the Acute Myeloid Leukemia market's trajectory is characterized by improved treatments, increased survival rates, and a commitment to reshaping the future of Acute Myeloid Leukemia are through innovation, collaboration, and patient-centric approaches.